J Korean Ophthalmol Soc.  2019 Feb;60(2):144-151. 10.3341/jkos.2019.60.2.144.

Meta-analysis of Intravitreal Injection of Anti-vascular Endothelial Growth Factors for Diabetic Macular Edema

• Tchoe H
• Shin SJ
• Suh JK
• Cho S
• Yang J
• Kang MJ
• Jee D

• KMID: 2438073
• DOI: http://doi.org/10.3341/jkos.2019.60.2.144

Abstract

PURPOSE
Intravitreal aflibercept, ranibizumab, bevacizumab, and dexamethasone are the most widely used drugs in the treatment of diabetic macular edema (DME). The aim of this study was to compare the efficacy and safety of anti-vascular endothelial growth factors and dexamethasone for the treatment of DME.
METHODS
There were nine previous systematic reviews on this topic; we updated these high-quality reviews. Seven studies were added to two studies following a literature search. Efficacy outcomes were 1) average improvement in visual acuity, 2) proportion of patients who experienced an improvement in vision (an increase in best-corrected visual acuity (BCVA) of ≥ 15 in the Early Treatment Diabetic Retinopathy Study [ETDRS]), and 3) proportion of patients who experienced worsening vision (a decrease in BCVA of ≥ 15 in the ETDRS). Safety outcomes included systemic adverse events and ocular-related adverse events.
RESULTS
The mean difference in the BCVA for ranibizumab versus bevacizumab treatment was 0.16 (95% confidence interval [CI]: −0.02, 0.34), and that for ranibizumab versus aflibercept was −0.08 (95% CI: −0.26, 0.10). The mean difference in the change of BCVA for aflibercept versus ranibizumab was −0.20 (95% CI: −0.40, −0.01), and that for aflibercept versus bevacizumab was −0.34 (95% CI: −0.53, −0.14). Other efficacy outcomes showed similar trends, and there was no significant difference between treatments. There was also no significant difference in both systemic and ocular adverse events rates between the treatments.
CONCLUSIONS
In DME patients, the efficacy of aflibercept was found to be higher with respect to BCVA changes compared with ranibizumab or bevacizumab. However, there were no significant difference in terms of visual acuity improvement or visual acuity of more than 15 letters, nor in terms of anti-vascular endothelial growth factors (as a safety outcome).

Keyword

Aflibercept; Anti-vascular endothelial growth factor; Diabetic macular edema; Ranibizumab

MeSH Terms

Bevacizumab
Dexamethasone
Diabetic Retinopathy
Endothelial Growth Factors*
Humans
Intravitreal Injections*
Macular Edema*
Ranibizumab
Visual Acuity
Bevacizumab
Dexamethasone
Endothelial Growth Factors
Ranibizumab

Reference

1. Hendrick AM, Gibson MV, Kulshreshtha A. Diabetic retinopathy. Prim Care. 2015; 42:451–464.

2. Frank RN. Diabetic retinopathy and systemic factors. Middle East Afr J Ophthalmol. 2015; 22:151–156.

3. Jee D, Lee WK, Kang S. Prevalence and risk factors for diabetic retinopathy: the Korea National Health and Nutrition Examination Survey 2008-2011. Invest Ophthalmol Vis Sci. 2013; 54:6827–6833.

4. Ashraf M, Souka AAR. Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. Eye (Lond). 2017; 31:1523–1536.

5. Villegas VM, Aranguren LA, Kovach JL, et al. Current advances in the treatment of neovascular age-related macular degeneration. Expert Opin Drug Deliv. 2017; 14:273–282.

6. Zhang Y, Chioreso C, Schweizer ML, Abràmoff MD. Effects of aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis of observational comparative studies. Invest Ophthalmol Vis Sci. 2017; 58:5616–5627.

7. Gemenetzi M, Patel PJ. A systematic review of the treat and extend treatment regimen with anti-vegf agents for neovascular age-related macular degeneration. Ophthalmol Ther. 2017; 6:79–92.

8. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372:1193–1203.

9. Jampol LM, Glassman AR, Bressler NM, et al. Anti-vascular endothelial growth factor comparative effectiveness trial for diabetic macular edema: additional efficacy post hoc analyses of a randomized clinical trial. JAMA Ophthalmol. 2016; 134:1429–1434.

10. Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol. 2013; 156:502–510.

11. Fouda SM, Bahgat AM. Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema. Clin Ophthalmol. 2017; 11:567–571.

12. Abouammoh MA. Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review. Can J Ophthalmol. 2013; 48:317–323.

13. Leveziel N, Ragot S, Gand E, et al. Association between diabetic macular edema and cardiovascular events in type 2 diabetes patients: a multicenter observational study. Medicine (Baltimore). 2015; 94:e1220.

14. Kwon JW, Jee D, La TY. The association between myocardial infarction and intravitreal bevacizumab injection. Medicine (Baltimore). 2018; 97:e0198.

15. Anothaisintawee T, Leelahavarong P, Ratanapakorn T, Teerawattananon Y. The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package. Clinicoecon Outcomes Res. 2012; 4:361–374.

16. Ford JA, Elders A, Shyangdan D, et al. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ. 2012; 345:e5182.

17. Korobelnik JF, Kleijnen J, Lang SH, et al. Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME). BMC Ophthalmol. 2015; 15:52.

18. Régnier S, Malcolm W, Allen F, et al. Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network metaanalysis. PLoS One. 2014; 9:e102309.

19. Mohamed QA, Fletcher EC, Buckle M. Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema. BMJ Clin Evid. 2016; 2016.

20. Virgili G, Parravano M, Evans JR, et al. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017; 6:Cd007419.

21. Ollendorf DA, Colby JA, Pearson SD. Comparative effectiveness of anti-VEGF agents for diabetic macular edema. Int J Technol Assess Health Care. 2013; 29:392–401.

22. Zhang L, Wang W, Gao Y, et al. The efficacy and safety of current treatments in diabetic macular edema: a systematic review and network meta-analysis. PLoS One. 2016; 11:e0159553.

23. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016; 123:1351–1359.

24. Wells JA, Glassman AR, Jampol LM, et al. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. JAMA Ophthalmol. 2016; 134:127–134.

25. Callanan DG, Loewenstein A, Patel SS, et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2017; 255:463–473.

26. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119:789–801.

27. Ekinci M, Ceylan E, Çakıcı Ö, et al. Treatment of macular edema in diabetic retinopathy: comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Rev Ophthalmol. 2014; 9:139–143.